Miglustat Dipharma



This medicine is authorised for use in the European Union.


Miglustat Dipharma is used to treat two inherited diseases that affect the way the body handles fats. Both diseases cause a build-up of fatty substances called glycosphingolipids in the body. Miglustat Dipharma is used to treat the following patients:

  • adults (aged 18 years and above) with mild to moderate type-1 Gaucher disease. Patients with this disease lack an enzyme called glucocerebrosidase, which results in a glycosphingolipid called glucosylceramide building up in different parts of the body, such as the spleen, liver and bones. Miglustat Dipharma is used in patients who cannot receive the standard treatment of enzyme- replacement therapy (ERT);
  • patients of all ages with Niemann-Pick type-C disease, a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body. Miglustat Dipharma is used to treat the neurological symptoms of the disease (symptoms affecting the brain and nerves). These include loss of coordination, problems with ‘saccadic’ (rapid) eye movements that can lead to impaired vision, delayed development, difficulty swallowing, decreased muscle tone, fits and learning

Miglustat Dipharma is a ‘generic medicine’. This means that Miglustat Dipharma contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Zavesca.

This EPAR was last updated on 30/01/2020

Authorisation details

Product details
Miglustat Dipharma
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Gaucher Disease
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Dipharma B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Prins Bernhardplein 200
1097 JB Amsterdam

Product information

13/12/2019 Miglustat Dipharma - EMEA/H/C/004904 - IA/0003


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.

Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.

Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.

Assessment history

How useful was this page?

Add your rating